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Aims Although hypokalaemia is common among patients with heart failure (HF), the prognostic significance of baseline
hypokalaemia and hypokalaemia during follow-up in HF patients receiving a mineralocorticoid receptor antagonist
(MRA) remains uncertain.
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Methods
and results
Results of the EMPHASIS-HF trial in patients (n = 2737) with HF and reduced EF with mild symptoms, randomized
to eplerenone or placebo, were analysed with regard to the presence or occurrence of hypokalaemia (serum K+
<4.0 mmol/L) and the risk of cardiovascular death or hospitalization for HF (primary endpoint). Median follow-up
was 21 months. Baseline hypokalaemia and hypokalaemia during follow-up were common occurrences (19.6% and
40.6%, respectively). Hypokalaemia during follow-up was associated with worse outcomes in multivariable analyses
[hazard ratio (HR) 1.26, 95% confidence interval (CI) 1.05–1.52, P = 0.01] without evidence of interaction with
eplerenone. In contrast, baseline hypokalaemia was associated with outcomes in the placebo group (HR 1.37, 95% CI
1.05–1.79, P = 0.02) but not in the eplerenone group (HR 0.87, 95% CI 0.62–1.23, P = 0.44; P for interaction= 0.04).
Concurrently, eplerenone was found to be more protective in patients with baseline hypokalaemia vs. patients without
baseline hypokalaemia compared with placebo (HR 0.44, 95% 0.30–0.64, P < 0.0001 vs. 0.69, 95% CI 0.57–0.83, P
= 0.0001; P for interaction= 0.04). In patients without baseline hypokalaemia, eplerenone use decreased the rate of
hypokalaemia during follow-up (HR 0.69, 95% CI 0.59–0.80, P < 0.001). A potassium level >4.0 mmol/L at 1 month
after randomization mediated 26.0% (0.6–51.4%) of the eplerenone treatment effect (P = 0.04).
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Conclusion In HF patients receiving optimal therapy but not treated with eplerenone, baseline hypokalaemia was associated with
worse outcomes. Conversely, hypokalaemia amplified the treatment effect of eplerenone.
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Introduction
Hypokalaemia is common among patients with heart failure (HF),
despite the use of inhibitors of the renin–angiotensin–aldosterone
system (RAAS). In spite of this, the fear of inducing worsening renal
function or hyperkalaemia has hampered the initiation or increase
in dosage of these lifesaving drugs in patients with HF and reduced
LVEF, who frequently have chronic kidney disease (CKD).1,2 Previ-
ous analyses in patients with HF noted poorer outcomes in those
with potassium levels <4.0 mmol/L defining hypokalaemia, while
incident hypokalaemia was shown to be attenuated by the use of
mineralocorticoid receptor antagonists (MRAs) in patients with
NYHA stage III–IV enrolled in the Randomized ALdactone Eval-
uation Study (RALES).3–6 We previously reported that, in patients
after myocardial infarction with LV dysfunction enrolled in the
Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy
and Survival Study (EPHESUS), an early rise in potassium levels at
1 month with the MRA eplerenone was associated with better
cardiovascular outcomes.7 The Eplerenone in Mild Patients Hos-
pitalization and Survival Study in Heart Failure (EMPHASIS-HF)
investigated the effects of eplerenone, added to evidence-based
therapy including RAAS inhibitors and beta-blockers on clinical out-
comes, in patients with systolic HF and mild symptoms (i.e. NYHA
functional class II symptoms). Eplerenone reduced the primary end-
point of cardiovascular death or HF hospitalization in comparison
with placebo when added to evidence-based therapy. Although the
use of eplerenone was associated with a higher incidence of wors-
ening renal function and hyperkalaemia, it retained its survival bene-
fits without any significant interaction with the association between
hyperkalaemia (>5.5 mmol/L) and worsening renal function and
worse outcomes.8 While hypokalaemia was reported by investiga-
tors as an adverse event, hypokalaemia tended to be less common
in the eplerenone group than in the placebo group (1.2% vs. 2.2%,
P= 0.05).9 Eplerenone furthermore induced a significant, early and
persistent, albeit modest, rise in serum potassium (of ∼0.1mmol/L
after 1 week).8 Because of protocol-mandated serial monitoring of
serum potassium, we were also able to analyse actual changes in
potassium, as opposed to merely investigator-reported events. In
the present study, we assessed the prevalence, incidence, associ-
ated factors, and prognostic significance of hypokalaemia at baseline
or occurring during follow-up in patients enrolled in EMPHASIS-HF.
We also assessed the interaction between prevalent hypokalaemia
and hypokalaemia during follow-up and the effect of eplerenone on
clinical outcomes.
Methods
Study design and patient population
The design and main results of the EMPHASIS-HF trial have previously
been reported.10 Of note, patients with a serum potassium >5.0
mmol/L, or an estimated glomerular filtration rate (eGFR)11 < 30
mL/min/1.73 m2 within 24 h prior to randomization or requiring
a potassium-sparing diuretic were not included. The study was
approved by an institutional review committee and the subjects
gave informed consent (ClinicalTrials.gov number, NCT00232180). A
post-hoc analysis was performed in all 2737 patients included in the ..
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.. EMPHASIS-HF trial. Median follow-up was 21 months. Per-protocol
dosing requirements based on serum potassium were performed
according to a therapeutic algorithm as previously reported.8
Briefly, serum potassium concentration was measured at 4 weeks
and at each subsequent clinic visit [every 4 months (Months 5,
9, 13, 17, 21, 25, 29, 33 and 37), then after 5 months (Month
42), and then after 6 months (Month 48), and subsequently at
6-month intervals until early termination or initiation into the open
label phase], with the dosage of study drug (placebo/eplerenone)
adjusted according to the algorithm. Additionally, the concen-
tration of serum potassium was verified 1 week after any dose
adjustment.
Endpoints
The primary efficacy endpoint for the EMPHASIS-HF trial was the
composite of cardiovascular mortality or hospitalization for HF.
Hospitalization for HF and cardiovascular mortality were secondary
endpoints. All endpoints were independently adjudicated by an inde-
pendent Critical Event Committee and were used for this post-hoc
analysis.
Statistical analysis
‘Hypokalaemia’ was defined as a serum potassium <4.0 mmol/L and
‘mild hypokalaemia’ as 3.5≤ serum K+ <4 mmol/L for sensitivity
analysis.3
Between-group assessments of baseline characteristics were per-
formed using t-tests for continuous variables and Fisher’s exact tests
for categorical variables.
The association between baseline characteristics and the presence
of baseline hypokalaemia was assessed using logistic regression models.
The following baseline covariates were chosen a priori, based on a
pathophysiological standpoint: study treatment, age, gender, ethnicity
(white vs. others), body mass index, systolic blood pressure, diastolic
blood pressure, heart rate, haemoglobin, EF, diabetes, history of
myocardial infarction, history of hospitalization for HF, eGFR, use
of ACE inhibitors or ARBs, percentage of ACE inhibitor or ARB
target dose, use of beta-blockers, percentage of beta-blocker target
dose, use of loop diuretics, daily dose of loop diuretics (furosemide
equivalents), use of other diuretics, use of digitalis, and intake of
potassium supplements. Analysis was performed either including all
covariates in the model or, for other models, using stepwise selection
to retain only those covariates shown to be significantly associated with
baseline hypokalaemia in the multivariable model (P< 0.05).
Cox proportional hazard regression models were used to exam-
ine the associations between the above covariates and the following
endpoints: (i) cardiovascular death or HF hospitalization (primary end-
point); (ii) cardiovascular death; and (iii) occurrence of post-baseline
hypokalaemia.
For the Cox regression analyses, patients who did not have an
endpoint event were censored at the date of death (non-cardiovascular
death for the primary endpoint or the endpoint of cardiovascular
death), date of withdrawal, or study cut-off date (25 May 2010),
whichever occurred first.
The interaction of treatment and baseline hypokalaemia or
hypokalaemia during follow-up on the rate of the primary endpoint
and on the rate of post-baseline hypokalaemia was examined using
Cox proportional hazard models similar to those described above.
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Table 1 Baseline characteristics according to hypokalemia at baseline or during follow-up
Baseline hypokalaemia Hypokalaemia during follow-up
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Patients with
basal K+ ≥4
mmol/L (n= 2201)
Patients with
basal K+ <4
mmol/L (n= 536)
P-value No K+ <4
during follow-upa
(n= 1625)
At least one
K+ <4 during
follow-upa (n=1112)
P-value
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Eplerenone 1096 (50%) 268 (50%) 1 870 (54%) 494 (44%) <0.0001
Demographic/clinical
characteristics
Age (years) 69± 8 68± 8 0.55 69± 8 68± 8 0.22
Male gender 1729 (79%) 398 (74%) 0.037 1283 (79%) 844 (76%) 0.062
Race
White 1880 (85%) 388 (72%) <0.0001 1402 (86%) 866 (78%) <0.0001
Other 321 (15%) 148 (28%) 223 (14%) 246 (22%)
Smoking status
Current smoker 235 (11%) 58 (11%) 0.005
Past smoker 1014 (46%) 207 (39%)
Never smoked 952 (43%) 271 (51%)
Body mass index (kg/m2) 28± 5 27± 5 0.0004 27.8± 5 27.2± 5 0.0022
LVEF (%) 26.2± 5 25.6± 5 0.007 26.4± 5 25.7± 5 <0.0001
Diabetes mellitus 700 (32%) 159 (30%) 0.35 537 (33%) 322 (29%) 0.024
eGFR (mL/min/1.7 3 m2) 71± 22 72± 22 0.21 70± 21 72± 22 0.0045
Baseline medications
Loop diuretic (%) 1660 (75%) 430 (80%) 0.020 1212 (75%) 878 (79%) 0.009
Loop diuretic (mg/day
furosemide equivalents)
64± 320 69± 71 0.54 67± 374 62± 57 0.70
Other diuretic (%) 387 (18%) 132 (25%) 0.0003 264 (16%) 255 (23%) <0.0001
ACE inhibitor, ARB, or
both (%)
2067 (94%) 490 (91%) 0.041 1529 (94%) 1028 (92%) 0.099
Percentage target dose of
ACE inhibitor or ARB
59± 68 56± 51 0.29 59± 70 58± 58 0.84
Beta-blocker (%) 1929 (88%) 445 (83%) 0.006 1448 (89%) 926 (83%) <0.0001
Percentage target dose of
beta-blockers
49±102 46± 72 0.47 50±106 47± 81 0.50
Digitalis glycosides (%) 586 (27%) 154 (29%) 0.33 411 (25%) 329 (30%) 0.014
Potassium supplements (%) 200 (9%) 60 (11%) 0.14 145 (9%) 115 (10%) 0.23
Values are expressed as means± standard deviation or n (%).
P-values were obtained from Student’s t-tests or Fisher’s exact tests when appropriate.
eGFR, estimated glomerular filtration rate.
aPotassium values collected after an occurrence of the primary endpoint were not considered in the determination of hypokalaemia during follow-up for this descriptive
analysis.
The interaction of treatment and hypokalaemia during follow-up
on the rates of the primary endpoint was also examined using Cox
proportional hazard models similar to those described above. How-
ever, for this analysis, hypokalaemia during follow-up was treated as
a time-varying factor, i.e. the model used an indicator variable for
this factor that assumed the value of 0 until the first occurrence of
hypokalaemia and the value of 1 thereafter. As a sensitivity analysis,
similar Cox proportional hazard analyses were also performed using
the incidence of hypokalaemia at Month 5 as the incident hypokalaemia
factor. For patients with events occurring prior to Month 5, the last
available post-baseline potassium measurement prior to the event was
used (last observation carried forward method).
All aforementioned baseline covariates chosen a priori, based on a
pathophysiological standpoint, were included as adjustment variables
in the multivariable Cox models. ..
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.. Kaplan–Meier curves were generated to illustrate the risk of end-
points in various participant subsets.
In a sensitivity analysis, the time to first hypokalaemia was estimated
by first using the midpoint between the visit at which hypokalaemia
was observed and the previous visit and second visit using linear
interpolation to estimate the time at which the potassium level
fell below 4.0. The results using either method were similar (data
not shown) to the original analysis. As our results were consistent
regardless of the method used, including the simplest method (no
interpolation), the latter was ultimately retained throughout the
present analysis.
To determine the portion of the eplerenone treatment effect
attributable to the early7 increase in potassium level above the
level defining hypokalaemia (as defined by a Month 1 level of ≥4.0
mmol/L), mediation analyses were performed using the %MEDIATE
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Table 2 Association between hypokalaemia and outcomes and interaction between hypokalaemia and eplerenone
treatment effect in multivariable Cox analysis
CV death or HFH (n= 605 events) CV death (n= 332 events)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
HR 95% CI P-value HR 95% CI P-value
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Effect of hypokalaemia in adjusted modelsa
Baseline hypokalaemia 1.14 0.93–1.41 0.22 1.20 0.91–1.58 0.20
Hypokalaemia during follow-up 1.26 1.05–1.52 0.01 1.47 1.16–1.86 0.002
Hypokalaemia at 5 months 1.38 1.12–1.71 0.003 1.55 1.18–2.02 0.001
Interaction between baseline hypokalaemia and
eplerenone treatment effect in adjusted modelsa
Eplerenone treatment effect in patients with baseline
hypokalaemia
0.44 0.30–0.64 <0.0001 0.52 0.32–0.84 0.008
Eplerenone treatment effect in patients without
baseline hypokalaemia
0.69 0.57–0.83 0.0001 0.79 0.61–1.03 0.08
Effect of baseline hypokalaemia in the placebo group 1.37 1.05–1.79 0.02 1.43 1.01–2.03 0.045
Effect of baseline hypokalaemia in the eplerenone
group
0.87 0.62–1.23 0.44 0.94 0.61–1.44 0.76
P for interaction= 0.04 P for interaction= 0.13
CI, confidence interval; CV, cardiovascular; HFH, heart failure hospitalization; HR, hazard ratio.
aTo ensure uniform adjustment in all Cox models, all relevant variables chosen a priori based on a pathophysiological standpoint were included in two interaction models
(CV death or HFH and CV death alone). Namely, the following adjustment variables were used: age, gender, ethnicity, body mass index, diastolic blood pressure, systolic
blood pressure, heart rate, haemoglobin, EF, diabetes, history of myocardial infarction, history of hospitalization for heart failure, estimated glomerular filtration rate, use of
beta-blockers, use of loop diuretics, daily dose of loop diuretics, use of other diuretics, receipt of potassium supplements, use of ACE inhibitors, ARBs, or both, percentage
of ACE inhibitor or ARB target dose, use of beta-blockers, percentage of beta-blocker target dose and use of digitalis.
macro developed by Hertzmark et al.12 based on the methods of
Lin et al.13
The macro, applied in patients with baseline hypokalaemia, com-
pared a model (Model 1) that included treatment as a factor (the
exposure) and an indicator for the increase in potassium level to ≥4.0
(the intermediate variable) with a model (Model 2) that eliminated the
intermediate variable. From the coefficient estimates, the proportion
mediated by the intermediate variable was calculated by the following
formula:
[1 – (estimate for treatment in model 2
∕estimate for treatment in model 1)
]
× 100
The standard error of the above estimate was calculated in the
manner of Lin et al.,13 using the values of the coefficient estimates as
well as the associated covariance matrix. A 95% confidence interval
(CI) was obtained by first using Fisher’s z transformation and the
delta method to obtain the 95% confidence limits of the transformed
estimate, followed by back-transforming to report the 95% CI on
the original scale. A similar analysis was performed to determine the
portion of the eplerenone treatment effect attributable to the increase
in potassium level above the level defining hypokalaemia at Month 5.
For patients with events occurring prior to Month 5, the last available
post-baseline potassium measurement prior to the event was used.
In the present analysis, odds ratios (ORs) and hazard ratios (HRs)
are presented with the associated 95% CI and P-value. For summaries
of categorical variables, count/total population and percentage are
presented. For summaries of continuous variables, mean± standard
deviation (SD) is presented.
A P-value of <0.05 was considered statistically significant for all
analyses except the analyses of interactions. Given the low power of .
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.. interaction tests,14–16 we,17 as others,16,18–20 selected a priori a 0.10
cut-off threshold for interaction P-values.
All analyses were conducted by Pfizer and inVentiv Health Clinical
with the original trial data set using SAS version 9.2 (SAS Institute,
Cary, NC, USA).
Results
Prevalence and factors associated
with baseline hypokalaemia
Patient characteristics according to the presence or absence of
baseline hypokalaemia and treatment allocation are described in
Table 1 (and Supplementary material online, Table S1 for mild base-
line hypokalaemia). Overall, baseline hypokalaemia was a common
occurrence (n= 536/2737, 20%), was mostly mild (n= 468/536,
87%), and equally distributed in both the eplerenone and placebo
groups. Of note, ∼10% of study participants across all subgroups
were receiving potassium supplements (Table 1; Supplementary
material online, Table S1).
In multivariable analysis, higher EF (OR 0.98, 95% CI 0.95–1.00,
P= 0.024), white ethnicity (OR 0.45, 95% CI 0.35–0.58, P< 0.001),
and history of diabetes (OR 0.78, 95% CI 0.62–0.97, P= 0.029)
were associated with a lower risk of baseline hypokalaemia.
In contrast, higher eGFR (OR 1.06 per 10 unit increase, 95%
CI 1.01–1.11, P= 0.014), loop diuretic use (OR 1.39, 95% CI
1.07–1.80, P= 0.014), and use of other non-potassium-sparing
diuretics (OR 1.83, 95% CI 1.43–2.34, P< 0.001) were significantly
associated with a higher risk of baseline hypokalaemia.
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Figure 1 Kaplan–Meier curves of cardiovascular (CV) death and/or heart failure (HF) hospitalization as a function of treatment in the
subgroups of patients with/without baseline K+ <4.0 mmol/L.
Prognostic value of baseline
hypokalaemia and interaction
with eplerenone
Survival curves in patients with and without baseline hypokalemia
are provided in Figure 1.
Overall, in multivariable analysis, baseline hypokalaemia was
not significantly associated with increased rates of the primary
outcome (HR 1.14, 95%CI 0.93–1.41, P= 0.22) and cardiovascular
death (Table 2).
Using a multivariable Cox model, a significant interaction was
identified between baseline hypokalaemia and eplerenone for the
primary outcome (P for interaction= 0.04). Importantly, baseline
hypokalaemia was significantly associated with poorer outcome
in the placebo group (HR 1.37, 95% CI 1.05–1.79, P= 0.02)
as opposed to no association with outcome in the eplerenone
group (Table 2). In addition, the magnitude of treatment effect of
eplerenone was greater in patients with baseline hypokalaemia (HR
0.44, 95% CI 0.30–0.64, P< 0.0001) (Figure 1; Table 2), a finding also
confirmed in a sensitivity analysis encompassing patients with mild
baseline hypokalaemia (HR 0.44, 95% CI 0.29–0.65, P< 0.001).
Incidence and factors associated
with hypokalaemia during follow-up
Overall, hypokalaemia during follow-up prior to the primary out-
come was common (40.6%), although far more frequent in the .
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. placebo group than in the eplerenone group [618/(618+ 755) or
45% vs. 494/(494+ 870) or 36%, P< 0.001]. When considering all
hypokalaemia during follow-up (i.e. including those occurring after
HF hospitalization), the same pattern was observed (overall 42.6%,
648/648+ 725 or 47% in the placebo group vs. 519/519+ 845 or
38% in the eplerenone group).
Univariable analysis of baseline features of patients experi-
encing hypokalaemia during follow-up are depicted in Table 1. In
multivariable analysis (Table 3), eplerenone use was associated
with a decreased rate of hypokalaemia during follow-up, while
hypokalaemia at baseline was strongly associated with a higher rate
of hypokalaemia during follow-up (HR 3.04, 95% CI 2.66–3.47,
P< 0.001). There was no significant interaction between base-
line hypokalaemia and eplerenone with regard to the rate of
hypokalaemia during follow-up (P for interaction= 0.40), suggest-
ing that eplerenone had a similar effect on rates of hypokalaemia
during follow-up in patients with and without hypokalaemia
at baseline. When focusing on patients without hypokalaemia
at baseline, higher eGFR, loop diuretics, other diuretics, and
potassium supplements were significantly associated with higher
rates of hypokalaemia during follow-up, whereas eplerenone was
associated with decreased rates of hypokalaemia during follow-up
(Table 3). Of note, patients with CKD (as defined by a baseline
eGFR <60 mL/min/1.73 m2) did not significantly differ from those
without CKD, regardless of the treatment group considered in
terms of hypokalaemia occurrence (see Supplementary material
online, Figure S1).
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Figure 2 Kaplan–Meier curves of the time to first occurrence of K+ <4.0 mmol/L during treatment in all study patients.
Prognostic significance of hypokalaemia
during follow-up and its interaction
with eplerenone treatment
In multivariable analysis, there was no significant interaction
between hypokalaemia during follow-up and eplerenone with
regard to the primary outcome (P for interaction= 0.44) or car-
diovascular mortality (P for interaction= 0.79). Similarly there was
no interaction between hypokalaemia at Month 5 and eplerenone
(P for interaction= 0.73).
Hypokalaemia during follow-up (coded as a time-dependent
variable) and hypokalaemia at 5 months were both significantly
associated with higher rates of the primary outcome and of
cardiovascular death (Table 2).
Mediation sensitivity analysis
In the subset of patients with baseline hypokalaemia, a significantly
greater percentage of patients in the eplerenone group exhibited
a serum K+ ≥4.0 mmol/L at Month 1 than in the placebo group
[186/268 (69.4%) vs. 138/268 (51.5%), P< 0.001]. For most demo-
graphics and baseline characteristics, no difference was observed
between patients with serum K+ ≥4.0 mmol/L and those with
serum K+ <4.0 mmol/L at Month 1 (data not shown). However,
a greater percentage of patients with serum K+ ≥4.0 mmol/L at
Month 1 were white as opposed to those with serum K+ <4.0
mmol/L at Month 1, both in the eplerenone [139/186 (74.7%) vs.
50/82 (61.0%), P= 0.03] and in the placebo [111/138 (80.4%) vs.
88/130 (67.7%), P= 0.02] groups. In addition, in the eplerenone
group, a lower percentage of patients with a serumK+ ≥4.0 mmol/L ..
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.. at Month 1 were receiving loop diuretics [142/186 (76.3%) vs.
72/82 (87.8%), P= 0.03].
Mediation analysis showed that the increase in serum potassium
above 4.0 mmol/L at 1 month after randomization mediated 26.0%
(0.6–51.4%) of the eplerenone treatment effect (P= 0.04). Similar
results were observed when considering the mean change in serum
potassium from baseline (proportion of mediation 21.7%, –3.2%
to 46.6%, P= 0.09). In contrast, a smaller proportion of the effect
was mediated by serum potassium concentration >4.0 mmol/L at
5 months after randomization (5.1%, –3.5% to 13.8%, P= 0.24).
Discussion
The present study provides valuable pathophysiological and prac-
tical insights into the beneficial effects of eplerenone in optimally
treated patients with HF and reduced EF. In the EMPHASIS-HF
study population, a significant proportion of patients were
hypokalaemic at baseline and during the conduct of the study,
a frequently underestimated condition associated with worse
outcomes. A minority (∼10%) of patients were receiving potas-
sium supplements at baseline. In this setting, based on interaction
tests, we show that the MRA eplerenone was even more protec-
tive when administered to optimally treated patients with HF and
reduced EF with mild symptoms, who were mildly hypokalaemic
at baseline (3.5≤K+ <4 mmol/L: 87% of hypokalaemic patients).
Moreover, hypokalaemia at baseline was associated with worse
outcomes only in patients treated with placebo. The relatively
high incidence of hypokalaemia in the present study suggests that
physicians may not be fully aware of the risk associated with mild
hypokalaemia. One could also suggest that the beneficial effects of
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Table 3 Association of baseline characteristics with hypokalaemia during follow-up
Hypokalaemia during
follow-up: all patients
Incident hypokalaemia during follow-up:
patients without baseline hypokalaemia
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
HR 95% CI P-value HR 95% CI P-value
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Eplerenone 0.72 0.64–0.81 <0.001 0.69 0.59–0.80 <0.001
Baseline hypokalaemia 3.04 2.66–3.47 <0.001 N/A N/A N/A
Race (white vs. others) 0.68 0.59–0.80 <0.001 0.72 0.59–0.89 0.002
BMI (for a 1 kg/m2 increase) – – – 0.98 0.97–1.00 0.047
LVEF (for a 1% increase) 0.98 0.96–0.99 <0.001 0.97 0.96–0.99 0.0005
Diabetes mellitus 0.86 0.75–0.98 0.03 0.83 0.70–0.98 0.03
eGFR (for a 10 mL/min/1.73 m2 increase) – – – 1.04 1.01–1.08 0.02
Loop diuretic 1.26 1.08–1.46 0.004 1.28 1.06–1.55 0.01
Other diuretic 1.32 1.14–1.54 <0.001 1.52 1.26–1.83 <0.0001
ACE inhibitor, ARB, or both 0.78 0.62–0.98 0.03 – – –
Beta-blocker 0.73 0.62–0.86 <0.001 0.69 0.56–0.85 0.0004
Potassium supplements – – – 1.32 1.03–1.69 0.03
BMI, body mass index; CI, confidence interval; eGFR, estimated glomerular filtration rate; HR, hazard ratio; N/A, not applicable.
MRAs shown herein, beyond their potential pleiotropic effects, may
be at least partly mediated by their potassium-sparing properties,
as already suggested by our previous results in patients with HF
post-myocardial infarction,7 and corroborated herein by our medi-
ation sensitivity analysis. Of note, hypokalaemia during follow-up
was also associated with worse outcomes in multivariable analyses,
independently of the major protective effect of eplerenone.
Hypokalaemia is common in patients with HF, in part because
of elevated aldosterone levels from neurohormonal activation
as well as from the use of diuretics. Accordingly, the use of
non-potassium-sparing diuretics was found herein to be associ-
ated with hypokalaemia both at baseline and during follow-up.
Aldosterone stimulates the exchange of sodium and potassium
in distal renal tubules, leading to excretion of potassium in the
urine.3 Potassium is an important determinant of myocardial func-
tion, and low serum potassium may cause arrhythmias and sud-
den cardiac death5 by accelerating depolarization, increasing auto-
maticity, and lengthening the action potential.4,21,22 Serum potas-
sium concentrations <4 mmol/L have previously been associ-
ated with increased mortality in the DIG (Digitalis Investigation
Group) trial.5,23 However, in our analysis, the risk associated with
hypokalaemia remained significant after adjusting for digitalis use
(data not shown).
Whether a further up-titration of RAAS inhibitors includ-
ing MRAs, prone to reset serum potassium concentrations to
the potassium range recommended by the American College of
Cardiology/American Heart Association guidelines (i.e. 4.0–5.0
mmol/L), could further maximize this benefit is an attractive
hypothesis and warrants further dedicated studies. Unfortunately,
it should be acknowledged that numerous registries have reported
a large and persistent gap between real-life practice in the use
of life-saving evidence-based therapies (such as RAAS inhibitors,
including MRAs) and recommended practices in international
guidelines. In any instance, a close monitoring of serum potas-
sium and renal function is essential during these periods of RAAS
inhibitor adjustments.1 Physicians should pay particular attention .
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.. not only to hyperkalaemia but to hypokalaemia as well, includ-
ing in patients with CKD, who are prone to experience adverse
outcomes,24 since these patients were found not to be protected
from hypokalaemia occurrence in the present analysis. In con-
trast, we previously showed that patients with lower GFR were
more prone to experience hyperkalaemia whilst receiving MRAs8
or increased ARB doses,25 although the latter did not hinder the
clinical benefit of these drugs.
Limitations
First, the present study was a post-hoc analysis and included
non pre-specified subgroups. Nevertheless, the present data are
derived from a substantial randomized controlled trial, thus allow-
ing us to assess reliably the association between eplerenone use,
baseline hypokalaemia, and the primary outcome adjudicated by
an endpoint committee. Moreover, a rigorous collection of serum
potassium was implemented. Secondly, these results were obtained
in patients with HF and reduced EF, presenting mild symptoms,
a serum potassium <5 mmol/L, and eGFR >30 mL/min/1.73 m2
at entry and therefore may not be applicable to patients with HF
and preserved EF. Moreover, there was frequent biochemical mon-
itoring during follow-up as well as implementation of an algorithm
to manage hyperkalaemia whilst down-titrating the study drug;8 in
addition, there were no pre-specified hypokalaemia management
rules. Therefore, the external validity and potential generalizability
to ‘real-world’ HF patients is uncertain.
In summary, the present data provide relevant pathophysiolog-
ical and practical insights, suggesting that in HF patients receiv-
ing optimal therapy but not treated with eplerenone, baseline
hypokalaemia is associated with worse outcomes. Conversely,
hypokalaemia amplifies the treatment effect of eplerenone com-
pared with placebo. Patients with a hypokalaemia during follow-up
are at increased risk of cardiovascular death and/or HF hospital-
ization and have a better prognosis when treated with eplerenone
compared with others. Greater attention should therefore be paid
© 2016 The Authors
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to screen for even mild hypokalaemia in patients with HF, and every
effort should be made to correct the latter, under close monitoring
of electrolyte balance and kidney function.
Supplementary Information
Additional Supporting Information may be found in the online
version of this article:
Figure S1. Kaplan–Meier curves of the time to first occurrence
of K+ <4.0 mEq/L during treatment according to the presence
or absence of chronic kidney disease at baseline (i.e. eGFR <60
mL/min/1.73 m2) in all study patients, in patients treated with
eplerenone, or those treated with placebo.
Table S1. Baseline characteristics in patients with 3.5≤K+ <4
mmol/L at baseline.
Table S2. Association between hypokalaemia and outcome and
interaction between hypokalaemia and eplerenone treatment effect
in alternative multivariable Cox analysis excluding treatment vari-
ables from adjustment variables.
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